SEC Form 4 · accession 0001209191-17-066649
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Phillip G. Febbo
Officer — Chief Medical Officer
Period of report
Dec 19, 2017
Accepted (ET)
Dec 20, 2017 · 4:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 19, 2017 | M | 5,000 | $27.00 | A | 23,134 | D | |
| Common StockF2,F3,F1 | Dec 19, 2017 | S | 5,000 | $37.00 | D | 18,134 | D | |
| Common StockF2,F3,F1 | Dec 19, 2017 | S | 334 | $36.82 | D | 17,800 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) HoldingF4 | $27.00 | Dec 19, 2017 | M | 5,000 | D | — | Feb 16, 2026 | Common Stock | 0 | 9,710 | D |
Explanation of responses
- F1Includes an aggregate of 17,800 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2017.
- F3Represents actual sale price.
- F4The option became exercisable as to 25% of the shares on February 16, 2017, and became exercisable as to 1/48th of the shares each full month thereafter.